Asia Pacific contrast and imaging agents in interventional X-ray market is projected to register a healthy CAGR of 5.8 % in the forecast period 2019 to 2026. The new market report contains data for historic years 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.
Market Segmentation
By Agent Type (Iodinated Contrast Media, Barium-Based Contrast Media, Microbubble Contrast Media, Gold Nanoparticle Contrast Agents, Others), Application (Cardiology, Gastroenterology, Neurology, Oncology, Urology, General Surgery), End User (Imaging Centers, Hospital, Clinics, Diagnostic Center, Ambulatory Surgical Centers, Private Practices), Country (China, Japan, India, Australia, South Korea, Singapore, Malaysia, Indonesia, Thailand, Philippines and rest of Asia-Pacific)
Major growing sectors under the market segmentation are as follows;
In agent type, iodinated contrast media is dominating as well as the fastest growing segment in this market.
In application, cardiology is dominating as well as the fastest growing segment in this market.
In end user, imaging centers is dominating as well as the fastest growing segment in this market.
Market Players
The key market players for Asia Pacific contrast and imaging agents in interventional X-ray market are listed below;
General Electric Company
BRACCO
Guerbet
Lantheus Medical Imaging, Inc.
FUJIFILM VisualSonics Inc.
Jodas Expoim
TAEJOON PHARM
Unijules Life Sciences Ltd.
J.B.Chemicals & Pharmaceuticals Ltd.
iMAX
Novalek Pharmaceuticals Pvt. Ltd.
Nano Therapeutics Pvt Ltd
Others